NovaBay receives $2.6M to advance Aganocide research

NovaBay Pharmaceuticals has received $2.6 million from partner Galderma for the clinical advancement of NovaBay’s “non-antibiotic, anti-infective” Aganocide compound NVC-422, a topical formulation for impetigo treatment.

Related Videos

View All

Related Content

The Weekly Roundup: January 16-20

January 20th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Drug Price Hikes Already Found in 2023

January 12th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

Positive Topline Results Announced for Oral Orismilast for Treatment of Psoriasis

January 9th 2023

The Weekly Roundup: January 2-6

January 6th 2023

The Weekly Roundup: January 16-20

January 20th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Drug Price Hikes Already Found in 2023

January 12th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

Positive Topline Results Announced for Oral Orismilast for Treatment of Psoriasis

January 9th 2023

The Weekly Roundup: January 2-6

January 6th 2023

The Weekly Roundup: January 16-20

January 20th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Drug Price Hikes Already Found in 2023

January 12th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

Positive Topline Results Announced for Oral Orismilast for Treatment of Psoriasis

January 9th 2023

The Weekly Roundup: January 2-6

January 6th 2023

Related Content

The Weekly Roundup: January 16-20

Articles

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

Podcasts

Drug Price Hikes Already Found in 2023

Articles

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

Podcasts

Positive Topline Results Announced for Oral Orismilast for Treatment of Psoriasis

Articles

The Weekly Roundup: January 2-6

Articles